Perrigo Company PLC (PRGO) Investment Analysis

1. Executive Summary:

Perrigo Company PLC (PRGO) is a leading global provider of over-the-counter (OTC) health and wellness solutions, operating with a distinct business model as a pure-play consumer self-care entity. Founded in 1887 by Luther Perrigo as a packager of patented medicines for country stores, the company has evolved through significant strategic pivots. Following the burdensome $7 billion acquisition of Elan in 2013, which saddled the firm with substantial debt, Perrigo systematically divested its generic prescription pharmaceutical and animal health divisions to focus exclusively on consumer self-care. Today, Perrigo is dedicated to empowering consumers to proactively prevent or treat conditions that can be self-managed, ensuring accessibility and choice across molecules, dosage forms, and value tiers.

The company’s revenue engine is designed around a complementary portfolio: it leverages highly cash-generative store-brand (private label) offerings to fuel investments in a stable of higher-margin, recognizable national and global brands. The organizational structure is bifurcated into two primary reportable segments:

Consumer Self-Care Americas (CSCA): This segment, encompassing operations in the United States, Mexico, and Canada, serves as the dominant core of the enterprise, historically accounting for approximately two-thirds of total consolidated net sales. Perrigo is the undisputed market leader in the U.S. store-brand OTC sector, supplying over half of the total domestic volume for private-label self-care products. The CSCA division manufactures and distributes a comprehensive array of products across several vital categories: Upper Respiratory (cough, cold, allergy, sinus), Pain and Sleep-Aids, Digestive Health, Nutrition (including infant formulas), Oral Self-Care, Skin Care, and Women's Health. The customer base for the CSCA segment is fundamentally business-to-business (B2B), supplying major global, national, and regional retail drug, supermarket, and mass merchandise chains.

Consumer Self-Care International (CSCI): The CSCI segment primarily serves Europe, Australia, and Israel, operating with a different strategic focus than its American counterpart. Rather than private-label dominance, the international division generates revenue predominantly through localized, national consumer health brands. In Europe, Perrigo ranks among the top 10 OTC companies by revenue, supported by a portfolio of high-growth brands such as Compeed, Solpadeine, Coldrex, EllaOne, Physiomer, and Jungle Formula.

Revenue Generation and Customer Concentration: Perrigo generates revenue by manufacturing and distributing over 100 molecular compounds across virtually 100% of consumer price points. By offering both premium branded solutions (like Opill, the first daily birth control pill available without a prescription in the U.S.) and affordable store-brand alternatives, the company captures consumers across the entire economic spectrum. However, this extensive distribution network relies heavily on a highly concentrated customer base. The company's top ten customers consistently account for roughly 46% to 47% of total consolidated net sales. Walmart Inc. remains the single most significant partner, representing 11.8% of consolidated net sales in recent fiscal years. Other critical retail and wholesale partners include Amazon, CVS Health, Walgreens Boots Alliance, Target, Costco, Dollar General, McKesson, and Cardinal Health.

2. Business Drivers & Strategic Overview:

Perrigo’s current strategic trajectory is governed by a comprehensive enterprise turnaround framework introduced by CEO Patrick Lockwood-Taylor, formally designated as the "Three-S Plan": Stabilize, Streamline, and Strengthen. This initiative, actively scaling into 2026 and 2027, aims to rewire the organization from a fragmented conglomerate into a unified "One Perrigo" operating model, capable of extracting higher returns on invested capital while navigating shifting macroeconomic realities.

The "Three-S" Strategic Framework

1. Stabilize: The foundational priority for management has been the stabilization of operations within the CSCA segment, with a specific focus on the U.S. store-brand OTC and infant formula businesses. The infant formula unit faced severe regulatory and operational headwinds following heightened FDA scrutiny and evolving industry guidelines throughout 2023 and 2024. After intense remediation efforts, Perrigo successfully restored its Wisconsin facility to a "No Action Indicated" regulatory status and recovered its store-brand market share to approximately 16%. However, broader infant formula market dynamics shifted rapidly, making the operationally intensive segment less aligned with Perrigo's core OTC health portfolio. Consequently, in November 2025, management initiated a formal strategic review of the Infant Formula business, halting a previously planned $240 million capacity investment to assess a full range of alternatives, including a potential sale or spin-off. A similar strategic review remains ongoing for the Oral Care business, as the company seeks to exit sub-scale or margin-dilutive operations.

2. Streamline: Perrigo has aggressively moved to simplify its global portfolio, operating model, and supply chain architecture. This objective is primarily executed through Project Energize, a three-year global investment and efficiency program launched in early 2024. Project Energize is designed to reset the SG&A expense base, condense management layers from seven regional clusters down to three, and centralize marketing and business services. The program targets annualized pre-tax savings of $140 million to $170 million by the end of 2026, with an expected net reduction of approximately 6% of the total global workforce. By late 2025, the company had already achieved a gross annual savings run-rate of $163 million, significantly ahead of schedule, allowing management to reinvest $40 million to $60 million into consumer-preferred innovation.

Concurrently, the company is rationalizing its physical portfolio. Between 2022 and 2024, Perrigo exited over 65 underperforming international brands and expects to streamline an additional 35 to 40 brands by 2027 to eliminate operational drag. Furthermore, the company successfully reached a definitive agreement to divest its Dermacosmetics business for up to €327 million (including a €300 million upfront cash payment), with closure expected in the first quarter of 2026. Proceeds from this divestiture are explicitly earmarked for debt reduction.

3. Strengthen: The final pillar involves reallocating the capital and organizational bandwidth saved from streamlining efforts toward high-growth, higher-margin categories. The company aims to drive $100 million to $200 million in incremental net sales by 2027 from its "High-Grow" brands. The strategic integration of the HRA Pharma acquisition (which added Compeed and EllaOne) and the launch of Opill are central to this growth vector. By prioritizing resource allocation toward Women's Health, Skin Care, and Pain Management, Perrigo intends to shift its product mix to structural higher-margin outputs.

Competitive Advantages

Perrigo possesses a distinct economic moat derived primarily from its unparalleled scale in the U.S. store-brand manufacturing space. By supplying over 50% of the U.S. store-brand OTC volume, the company benefits from immense economies of scale that are exceedingly difficult for new entrants to replicate. The regulatory barriers to entry in the pharmaceutical sector are exceptionally high; securing Abbreviated New Drug Applications (ANDAs) and maintaining strict FDA-compliant manufacturing environments for hundreds of individual SKUs requires massive sunk costs, specialized infrastructure, and decades of institutional knowledge.

Furthermore, the company's domestic manufacturing footprint provides a structural, geoeconomic advantage. Operating 11 manufacturing facilities across the United States allows Perrigo to produce 85% of its finished goods locally, utilizing a supply chain where 50% of materials and components are sourced domestically. While the company remains exposed to international Active Pharmaceutical Ingredient (API) markets, this geographic concentration partially insulates Perrigo from global freight shocks and provides agility in fulfilling domestic retail demand compared to competitors reliant entirely on offshore production.

Revenue Drivers

Perrigo's top-line performance is highly tethered to total consumer consumption volumes within the health and wellness space, the epidemiological severity of the annual cold and flu season (driving the Upper Respiratory category), and broader macroeconomic conditions. During periods of inflation, economic strain, or consumer wallet fatigue, Perrigo structurally benefits from the "trade-down" effect. As disposable income tightens, consumers abandon higher-priced national brands in favor of affordable, clinically equivalent store-brand alternatives. This counter-cyclical dynamic was evident in the third quarter of 2025; while the overall OTC market experienced soft consumption, Perrigo gained dollar, unit, and volume share across 5 of its 7 OTC categories, outperforming the underlying market.

3. Financial Performance & Valuation:

Perrigo’s financial performance through the conclusion of 2025 illustrates a company deep in transition, working to balance structural market share gains against broad consumer market softness, strategic asset reviews, and a heavily levered capital structure.

2025 Historical Performance Summary

For the nine months ended September 27, 2025 (Year-to-Date), Perrigo reported net sales of $3.14 billion, representing a 2.8% decline year-over-year. Favorable foreign exchange translation was more than offset by a 1.7% contraction in organic net sales and a 1.9% headwind from divestitures and exited products. Despite the top-line pressure, reported operating income for the period showed significant improvement, reaching $165 million.

Focusing on the most recent reporting period, the Third Quarter of 2025, net sales were $1.04 billion, a decline of 4.1% year-over-year. The organic decline of 4.4% was heavily skewed by the underperformance of businesses currently under strategic review (Infant Formula and Oral Care), which collectively dragged total organic growth down by 2.8%. The remaining global OTC business declined by 1.6%, primarily due to soft overall market consumption, even as Perrigo actively captured market share from competitors.

Despite these revenue headwinds, the margin profile demonstrated resilience due to the aggressive execution of Project Energize and the Supply Chain Reinvention program. Adjusted operating income for Q3 2025 was $173 million, representing a 4.9% decline year-over-year, but adjusted operating margins contracted only slightly by 20 basis points to 16.6%. Adjusted diluted earnings per share (EPS) for the quarter was $0.80, down minimally from $0.81 in the prior year, yet exceeding Wall Street consensus estimates of $0.76, marking a positive earnings surprise.

Updated Fiscal 2025 Guidance

In November 2025, confronting slower-than-anticipated infant formula share recovery and sustained softness in aggregate OTC consumption, management issued a downward revision to its full-year 2025 financial outlook. The updated metrics are as follows:

• Reported Net Sales Growth: Expected to decline by -2.5% to -3.0%.

• Organic Net Sales Growth: Expected to decline by -2.0% to -2.5%.

• Adjusted Gross Margin: Projected to hold at approximately 39.0%.

• Adjusted Operating Margin: Projected to be approximately 15.0%.

• Interest Expense: Estimated at approximately $155 million.

• Adjusted Effective Tax Rate: Expected to be approximately 18.5%.

• Adjusted Diluted EPS: Targeted between $2.70 and $2.80, representing a year-over-year growth of 5% to 9% from the 2024 base of $2.57.

Cash Flow and Balance Sheet Metrics

Cash flow generation and debt reduction remain existential priorities for the firm. The company targets an operating cash flow conversion rate to adjusted net income of approximately 100%. Through the first nine months of 2025, operating cash flow stood at $63 million, severely hindered by a $65 million outflow in the first quarter required to rebuild infant formula inventory, settle outstanding legacy litigation (including a $97 million final funding for the Omega Pharma price-fixing class action), and cover Project Energize restructuring costs.

The balance sheet is highly constrained. As of the end of Q3 2025, the company carried $432 million in cash and cash equivalents against a formidable long-term debt load of approximately $3.64 billion. Consequently, the net leverage ratio target for year-end 2025 was revised upward to approximately 3.8x Adjusted EBITDA (from a prior target of 3.5x), reflecting lower absolute EBITDA generation than initially forecasted.

Current Valuation Multiples

Trading in the range of $14.58 to $14.97 as of late February 2026, Perrigo’s valuation reflects profound market skepticism regarding its leverage and growth trajectory.

• Price-to-Earnings (P/E): On a trailing GAAP basis, the P/E ratio is sharply negative (-38.4x to -39.7x) due to massive non-cash amortization of acquired intangibles, restructuring charges, and legal settlements. However, on a forward-adjusted basis, utilizing the midpoint of 2025 EPS guidance ($2.75), the stock trades at an exceptionally depressed multiple of approximately 5.3x to 5.4x forward earnings.

• Enterprise Value-to-EBITDA (EV/EBITDA): Factoring in the substantial debt load, the firm trades at an enterprise value of roughly $5.2 billion, equating to a multiple of approximately 7.1x EV/EBITDA.

• Price-to-Sales (P/S): The stock trades at a heavily discounted 0.5x trailing sales.

When benchmarked against diversified consumer health peers such as Haleon or Kenvue—which frequently command mid-to-high teens EV/EBITDA multiples and high-teens forward P/E ratios—Perrigo is priced at a severe distressed discount. This valuation chasm accurately prices in the company's lack of top-line organic growth, elevated debt levels, and a history of execution missteps.

4. Risk Assessment & Macroeconomic Considerations:

Investing in Perrigo carries substantial risk, governed by a confluence of geopolitical dynamics, macroeconomic consumer trends, and structural balance sheet vulnerabilities.

Macroeconomic and Geopolitical Risks

1. Tariff Exposure and Supply Chain Concentration: While Perrigo prides itself on its localized U.S. manufacturing network, it remains heavily dependent on international supply chains, particularly in Asia, for Active Pharmaceutical Ingredients (APIs) and specialized components. The evolving geopolitical environment and the imposition of global trade tariffs present a material threat to gross margins. In late 2025, management explicitly modeled the impact of anticipated tariffs, projecting a gross increase to the global cost of goods sold of approximately $40 million to $50 million for 2025, primarily impacting the Oral Care product category where approximately 50% of procured goods are sourced from China. While the company intends to mitigate these costs through strategic pricing actions and supply chain insourcing, the elasticity of consumer demand strictly limits how much price can be passed on before market share is surrendered to discount competitors.

2. Consumer Wallet Fatigue: The broader OTC market experienced significant consumption softness throughout 2024 and 2025. While persistent inflation theoretically drives consumers down the value chain to Perrigo's cheaper store brands, absolute volume declines in the marketplace indicate a more troubling trend: consumers are either rationing self-care expenditures entirely, extending the life of current products, or substituting with home remedies. If the total addressable market volume contracts faster than Perrigo can capture private-label share, absolute revenue will inevitably decline regardless of relative outperformance.

Business and Operational Risks

1. Debt Burden and Interest Rate Sensitivity: Perrigo operates with a precarious capital structure. Carrying $3.64 billion in total debt against a market capitalization of roughly $2.0 billion yields a net leverage ratio of 3.8x. This restricts financial agility. The annual interest expense, projected at $155 million for 2025, consumes a massive portion of operating cash flow. While management has mitigated immediate variable rate risk by utilizing interest rate swaps to fix the rate on greater than 90% of outstanding debt, the sheer volume of principal limits capital allocation optionality, virtually eliminating the possibility of share repurchases or aggressive M&A until leverage is tamed.

2. Customer Concentration Power Dynamics: Perrigo’s reliance on a consolidated cohort of mega-retailers is a persistent structural risk. With Walmart alone accounting for nearly 12% of revenue and the top ten customers driving roughly 46% of total sales, retail partners wield immense negotiating leverage. These distributors dictate terms regarding wholesale pricing, shelf space allocation, and inventory management. Should a major partner pivot its private-label strategy, demand higher trade promotions, or delist Perrigo SKUs, the resulting revenue and margin impact would be immediate and severe.

3. Regulatory Scrutiny and Quality Control: As a manufacturer of OTC drugs and infant formulas, Perrigo operates in a hyper-regulated environment governed by the FDA and the EMA. The FDA’s evolving industry guidelines and heightened inspection standards for infant formula facilities severely disrupted operations and destroyed shareholder value between 2023 and 2024. Any future Form 483 observations, manufacturing deviations, or product recalls across its 11 U.S. facilities could result in catastrophic revenue destruction, brand damage, and extensive remediation costs.

4. Execution Risk on Divestitures: The "Three-S" turnaround strategy is heavily reliant on the successful execution of asset divestitures. The company expects to close the sale of the Dermacosmetics unit in Q1 2026 and is seeking strategic resolutions for the Infant Formula and Oral Care businesses. If macroeconomic conditions tighten or private equity buyers balk at valuations, these assets may fail to sell. Retaining these operationally intensive, lower-margin divisions would result in stranded overhead costs, thwarting the anticipated margin expansion and deleveraging timelines.

5. 5-Year Scenario Analysis:

To determine a realistic probability-weighted target price for early 2031 (5 years from current early 2026 data), three distinct scenarios are projected. All scenarios value the business based on forward Adjusted EPS multiples. Non-core segments under strategic review (Infant Formula and Oral Care) are assumed divested in the Base and High cases to accurately model the "Streamline" strategic intent, with proceeds aggressively applied to debt reduction.

Core Baseline Assumptions:

• Current Stock Price: ~$14.80 (As of Feb 2026).

• Current Shares Outstanding: ~138.5 million.

• Current Total Debt: ~$3.64 billion.

• Current Net Leverage: 3.8x Adjusted EBITDA.

• Target Leverage: Management targets < 3.0x by 2027.

Scenario 1: Base Case (The "Muddle Through" Turnaround)

The Key Fundamentals: In this scenario, management successfully executes the core tenets of the "Three-S" plan, but macroeconomic headwinds limit exceptional outperformance. The Dermacosmetics unit closes for €327M in Q1 2026. The Infant Formula and Oral Care businesses are sold by the end of 2026, though at depressed multiples (e.g., 0.8x sales) due to regulatory history and market softness, netting approximately $400 million combined. The total liquidity from divestitures (~$750 million) is deployed immediately to retire high-yield debt. This critical action removes roughly $40 million in annual interest expense, heavily boosting EPS.

The remaining core OTC business achieves a modest 2.0% organic sales CAGR (falling below management's stated 2.5%-4.5% target) due to persistent consumer wallet fatigue. Project Energize savings ($160M+) are fully realized, structurally lifting adjusted operating margins to 16.5%.

Financial Trajectory: Divestitures mechanically shrink the top-line revenue base to ~$3.8 billion by 2027. However, core growth pushes revenue back to ~$4.1 billion by 2030. Adjusted EPS grows steadily from the $2.75 base in 2025 to $3.50 by 2030, aided heavily by lower interest costs and operational margin recovery, rather than explosive sales growth.

Valuation Multiple: The market rewards the simplified corporate structure and lower leverage (<3.0x) with a slight multiple expansion. The stock rerates to 8.0x forward EPS, which remains a steep discount to consumer staple peers, reflecting the market's long memory of historical execution trauma. Projected Share Price Outcome: 8.0x * $3.50 = $28.00.

Scenario 2: High Case (The "Consumerization" Triumph)

The Key Fundamentals: The strategic plan is executed flawlessly. Inflation remains sticky, forcing a permanent consumer shift toward Perrigo's store brands. The "High-Grow" branded portfolio (Opill, Mederma) achieves the $200 million incremental sales target by 2027, vastly improving product mix. Divestitures execute at premium valuations (1.2x sales to strategic buyers), generating over $850 million in total debt reduction. Asian tariffs are successfully mitigated via accelerated U.S. insourcing and passed directly to retail partners. Organic top-line growth consistently hits the high end of management's target at 4.0% CAGR.

Financial Trajectory: Core revenue approaches $4.5 billion by 2030. Operating margins expand aggressively to 17.5% due to operational leverage and favorable brand mix. Adjusted EPS compounds at 10% annually post-divestiture, reaching $4.40 by 2030. Debt leverage plummets below 2.5x, allowing Perrigo to reauthorize stock buybacks, reducing the share count to 125 million by 2030.

Valuation Multiple: A clean, growing, highly cash-generative consumer health company without the drag of infant formula remediation commands a rerating closer to industry averages. The multiple expands to 11.0x forward EPS. Projected Share Price Outcome: 11.0x * $4.40 = $48.40.

Scenario 3: Low Case (The "Debt Trap" Stagnation)

The Key Fundamentals: Macroeconomic pressures abate, inflation cools, and consumers willingly trade back up to premium national brands, stalling store-brand volume growth. Tariffs escalate and cannot be fully offset, permanently compressing gross margins to 37%. Private equity and strategic buyers balk at the Infant Formula and Oral Care assets, forcing Perrigo to retain and operate these underperforming, capital-intensive divisions. Debt remains stubbornly above 3.5x. Project Energize savings are entirely consumed by wage inflation and increased retailer promotional demands.

Financial Trajectory: Organic sales stagnate at 0%. Revenue hovers around $4.2 billion for the 5-year period. Interest expense remains an anchor on cash flows. Adjusted EPS languishes, declining slightly from the 2025 base to settle around $2.30 by 2030 as margins compress.

Valuation Multiple: The market permanently treats Perrigo as a structural value trap. Institutional abandonment keeps the multiple distressed at 5.0x forward EPS. Projected Share Price Outcome: 5.0x $2.30 = $11.50.

Share Price Trajectory & Probability Weighting

Probability-Weighted Target Calculation:

• Base: $28.00 0.55 = $15.40

• High: $48.40 0.20 = $9.68

• Low: $11.50 0.25 = $2.87

• Expected 5-Year Value: $27.95

DEEPLY DISCOUNTED TURNAROUND

6. Qualitative Scorecard:

The following metrics assess the fundamental health, operational execution, and alignment of Perrigo Company PLC, scored on a scale of 1 to 10.

• Management Alignment (5/10): Insider ownership is remarkably low, with executives and directors collectively holding roughly 0.43% of outstanding shares (representing approximately 660,335 shares worth ~$18 million). The vast majority of the equity (99.5%) is held by institutional investors. While the company imposes rigid stock ownership guidelines (mandating the CEO hold 6x their base salary and EVPs 3x), actual skin in the game is negligible compared to total enterprise scale. Executive compensation is appropriately structured—with 85% of the CEO's pay tied to performance metrics and at-risk elements—but the lack of outright baseline ownership tempers the score.

• Revenue Quality (7/10): The revenue base is highly resilient. Self-care products, OTC medicines, and infant nutrition are largely non-discretionary purchases, buffering the top line against severe recessions. However, the quality is slightly diluted by heavy customer concentration (Walmart and other major chains dictate terms) and the structural lower-margin nature of the private-label model compared to proprietary pharma.

• Market Position (8/10): Perrigo is an absolute juggernaut within its specific niche. It commands over 50% of the U.S. store-brand OTC volume. Even in a soft macroeconomic market in 2025, it achieved six consecutive months of OTC store brand volume share gains and gained share in 5 out of 7 product categories. The company is decisively winning the micro-battles, even if the macro war is challenging.

• Growth Outlook (4/10): The top line is fundamentally stagnant. Management was forced to revise 2025 organic growth guidance downward to a contraction of -2.0% to -2.5%. While the "High-Grow" branded portfolio offers a silver lining, the core store-brand business operates in a mature, low-growth, GDP-linked segment. Furthermore, impending strategic divestitures will mathematically shrink absolute revenue over the next 24 months.

• Financial Health (4/10): The balance sheet is a glaring vulnerability. Carrying over $3.64 billion in debt with a net leverage ratio of 3.8x is highly precarious in a higher-for-longer interest rate environment. While interest coverage remains adequate and operating cash flow generation is consistently positive, the debt load limits strategic agility and leaves zero margin for operational error.

• Business Viability (9/10): The long-term durability of the business is exceptionally high. As long as retail pharmacies exist and humans experience coughs, allergies, and pain, Perrigo will have an enduring market. The primary choke points involve FDA compliance and API sourcing from Asia , but the core business model is effectively permanent.

• Capital Allocation (5/10): Management has an inconsistent history regarding capital allocation, highlighted by the disastrous Elan acquisition and the troubled Omega Pharma purchase that resulted in a $97 million price-fixing settlement in 2024. However, recent moves appear disciplined. The commitment to paying down debt, exiting low-margin/high-headache businesses like Infant Formula, and maintaining a 23-year streak of dividend increases (currently yielding ~7.8%) demonstrates a deliberate shift toward prudent, shareholder-friendly capital preservation.

• Analyst Sentiment (6/10): Wall Street is cautiously ambivalent. The consensus rating leans toward a "Hold" or weak "Buy," with an average 12-month price target resting between $18.67 and $21.00. Analysts clearly recognize the deep value inherent in the depressed multiple but remain deeply skeptical of execution given historical letdowns.

• Profitability (6/10): On a GAAP basis, profitability is consistently marred by non-cash amortization, constant restructuring charges, and impairments. However, adjusted operating margins are healthy (~15% to 16.6%) and expanding due to supply chain reinvention and Project Energize. Free cash flow conversion remains excellent, routinely hitting >100% of adjusted net income, ensuring the debt can be serviced.

• Track Record (2/10): The 10-year track record is one of profound shareholder value destruction. From an all-time high of over $160 in 2015 to roughly $14 in early 2026, long-term investors have suffered immensely through ill-timed acquisitions, tax disputes, prolonged litigation, and operational missteps.

Overall Blended Score: 5.6 / 10

MIXED FUNDAMENTAL REALITY

7. Conclusion & Investment Thesis:

Perrigo presents a classic, albeit complex, turnaround proposition characterized by a stark dichotomy: a deeply depressed valuation paired against a heavily burdened balance sheet.

The core investment thesis hinges entirely on the successful execution of the "Three-S" strategy (Stabilize, Streamline, Strengthen). At approximately 5.4x forward adjusted EPS, the market is pricing Perrigo as an entity in permanent, terminal decline. However, the underlying cash-generation engine remains intact. The company is actively winning market share in the U.S. OTC space, proving that its value proposition resonates strongly with consumers during periods of economic fatigue. Furthermore, Project Energize is delivering tangible, structural cost savings that are actively defending operating margins despite top-line contraction.

Key Catalysts: The primary catalysts for a rerating lie in portfolio simplification and deleveraging. If management successfully executes the divestiture of the Infant Formula and Oral Care units—following the already signed Dermacosmetics deal—the proceeds could materially reduce the $3.64 billion debt load. Moving net leverage below 3.0x would drastically de-risk the equity and likely trigger an expansion in the P/E multiple as enterprise value shifts from debt to equity. Additionally, further volume growth in the high-margin women's health portfolio (Opill) serves as a potent margin-accretive catalyst.

Major Risks: Conversely, the thesis is highly sensitive to execution failure. Should the company be unable to secure buyers for its non-core assets at reasonable multiples, it will be forced to continue funneling capital into the operationally intensive Infant Formula segment. Furthermore, estimated gross tariff impacts of $40 million to $50 million threaten to compress margins if strategic pricing actions and supply chain insourcing fail to mitigate the costs.

Ultimately, Perrigo is a highly durable business operating with a fragile capital structure. It represents an asymmetric setup heavily reliant on management's ability to seamlessly execute asset sales and redirect cash flows toward aggressive debt reduction.

HIGH EXECUTION REQUIRED

8. Technical Analysis, Price Action & Short-Term Outlook:

From a technical perspective, PRGO stock remains mired in a pronounced long-term downtrend. Trading in the mid-to-high $14 range as of late February 2026, the price sits significantly below its 200-day simple moving average (SMA), which hovers near $17.92 to $20.70. This negative divergence underscores sustained bearish momentum and heavy overhead supply. However, recent price action indicates signs of short-term stabilization. Following the abrupt ~25% selloff in November 2025 (precipitated by the Q3 revenue miss and the announcement of the Infant Formula strategic review), the stock has consolidated sideways. Short-term moving averages are beginning to flatten, and momentum oscillators like the RSI have drifted from oversold territory toward neutral levels (52 to 63). The short-term outlook hinges entirely on the impending Q4 2025 earnings release on February 26, 2026; a beat on EPS or clarity on divestitures could spur a mean-reversion rally, while a miss will likely trigger a retest of 52-week lows.

BEARISH BUT STABILIZING